首页> 外文OA文献 >799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve

【2h】

799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve

机译：799 - upadacitinib作为患者对患者适度到严重活性溃疡性结肠炎的诱导治疗的疗效，有或没有先前治疗的生物治疗失败：来自剂量范围的第2B期的数据研究U-实现

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Remo Panaccione; Geert R. DHaens; William J. Sandborn; Subrata Ghosh; Stefan Schreiber; Satoshi Tanida; Wen Zhou; Fabio Cataldi; David Pugatch; Bidan Huang; Wangang Xie; Peter D. Higgins;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY [J] . Feagan B G, Loftus E V, Danese S, Journal of the Canadian Association of Gastroenterology . 2021,第Supplementa1期

机译：菲尔替尼作为患者适度患者对严重活性溃疡性结肠炎的诱导治疗的疗效和安全性：来自2B / 3选择研究的结果
2. EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY [J] . Peyrin-Biroulet L, Loftus E V, Danese S, Journal of the Canadian Association of Gastroenterology . 2021,第Supplementa1期

机译：菲尔替尼的疗效和安全性作为患者适度到严重活性溃疡性结肠炎的患者：结果2B / 3选择研究结果
3. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy [J] . Tappenden Paul, Ren Shijie, Archer Rachel, PharmacoEconomics . 2016,第10期

机译：常规治疗失败后中，重度活动性溃疡性结肠炎成人治疗的基于生物学和非生物学选择的基于模型的经济评估
4. Synbiotic Therapy Significantly Reduces Molecular Markers of Inflammation and Clinical Scores in Patients with Active Ulcerative Colitis; A Randomised Controlled Trial [C] . Controlled Release Society annual meeting . 2004

机译：同步治疗显着减少了活性溃疡性结肠炎患者的炎症和临床评分的分子标记;随机对照试验
5. Efficacy of the Specific Carbohydrate Diet for the Treatment of Patients with Active, Severe, Biologic-Refractory Inflammatory Bowel Disease [D] . Dabbah, Eliane. 2020

机译：特定碳水化合物饮食治疗活性，严重，生物难治性炎症肠病患者的疗效
6. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY [O] . L Peyrin-Biroulet, E V Loftus Jr, S Danese, 2021

机译：A17菲霉素作为患者的疗效和安全性对患者适度到严重活性溃疡性结肠炎：2B / 3选择研究的结果
7. OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study [O] . W J Sandborn, S Schreiber, S D Lee, 2019

机译：OP14改善了Upadacitinib的内窥镜结果和粘膜愈合作为成年人的诱导治疗，以适度到严重活跃的溃疡性结肠炎：来自U-attest研究的数据

799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve

著录项

相似文献

相关主题

期刊订阅